Spruce Biosciences, Inc. Overview
Pro stress-test →Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. The company's lead candidate, TA-ERT (tralesinidase alfa), is pursuing FDA approval for Sanfilippo Syndrome Type B and recently received FDA Breakthrough Therapy designation, positioning the company for near-term regulatory milestones.
Strategic Profile
Pro stress-test →Spruce is transitioning from clinical-stage to commercialization, with a diversified pipeline including programs for major depressive disorder (Tildacerfont), Congenital Adrenal Hyperplasia (SPR202), and post-bariatric hypoglycemia (SPR204). The company has strategic partnerships with Eli Lilly and Kaken Pharmaceutical, enhancing development and geographic reach while maintaining a lean operational structure.
Competitive Landscape
Pro stress-test →Spruce operates in the rare neurological disease space competing with companies like Sesen Bio, Palisade Bio, and other late-stage biotech programs targeting lysosomal storage disorders. The TA-ERT enzyme replacement therapy space is relatively uncrowded for Sanfilippo Type B specifically, providing potential first-mover advantage. Partnerships with established pharma (Eli Lilly) differentiate the company and de-risk development.
Industry Context
Spruce Biosciences, Inc. operates in Biopharmaceutical - Rare Diseases & Neurological Disorders.
Key facts
Founded: 2014 · Headquarters: South San Francisco, California · Employees: 9 · Market cap: $91M